Drug intelligence / Profile preview

RVT-504

Development stage: Discontinued
Lead developer: Dermavant Sciences
Modality: Small Molecules
Administration: Oral

Overview

**RVT-504** is an investigational oral fixed-dose combination drug consisting of the muscarinic antagonist **oxybutynin** (7.5 mg) and the muscarinic agonist **pilocarpine** (7.5 mg) in a twice-daily formulation utilizing proprietary technology to control pilocarpine release and dosing. Developed initially by **TheraVida** and licensed to **Dermavant Sciences**, it aims to treat **primary focal hyperhidrosis** (excessive sweating) by leveraging oxybutynin's anticholinergic effects to reduce sweating while mitigating common side effects like dry mouth through pilocarpine's salivary stimulation.[1][2][9]

Brand names: Anhydrix
Other names: oxybutynin/pilocarpine

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on RVT-504.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RVT-504.

Explore the full profile